10-Q: Cosmos Health Inc. Reports Third Quarter 2024 Results Amidst Going Concern Uncertainty

Sentiment:

Quarterly Report 14 November 2024 4:53 PM

Cosmos Health Inc. reported its third quarter 2024 results, showing a slight decrease in revenue compared to the same period last year, while also expressing substantial doubt about its ability to continue as a going concern.

Capital raiseThe company plans to raise additional equity funds through utilizing its outstanding warrants.The company has sold 901,488 shares of common stock for net proceeds of $629,426 through two Prospectus Supplements.The company plans to file with the U.S. SEC a registration statement on Form S-1 for an offering of up to $7.5 million by the end of November 2024.

Worse than expectedThe company's net loss increased for the nine-month period compared to the same period last year.The company's management has expressed substantial doubt about its ability to continue as a going concern.

Summary

Cosmos Health Inc. reported a revenue of $12.4 million for the third quarter of 2024, a slight decrease from $12.8 million in the same period of 2023.
The company's net loss for the quarter was $2.2 million, an improvement compared to a net loss of $3.4 million in the third quarter of 2023.
For the nine months ended September 30, 2024, revenue was $40.2 million, an increase from $37.5 million in the same period of 2023.
The net loss for the nine-month period was $6.6 million, compared to a net loss of $4.8 million in the same period of 2023.
The company's management has expressed substantial doubt about its ability to continue as a going concern due to its inability to sustain operations with current revenues and concerns about meeting obligations.
As of September 30, 2024, the company had a working capital of $11 million, an accumulated deficit of $104.5 million, and stockholders' equity of $35 million.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning and increased losses, despite some revenue growth and capital raising efforts. The overall tone is concerning from an investment perspective.

Positives

The net loss for the third quarter of 2024 improved compared to the same period in 2023.
Revenue for the first nine months of 2024 increased compared to the same period in 2023.
The company successfully raised $4.2 million through a warrant inducement program.
The company secured additional debt financing of $432,760 through its subsidiary Cosmofarm SA.
The company sold 901,488 shares of common stock for net proceeds of $629,426.

Negatives

Third quarter revenue decreased slightly compared to the same period last year.
The company's net loss for the first nine months of 2024 increased compared to the same period in 2023.
Management has expressed substantial doubt about the company's ability to continue as a going concern.
The company has an accumulated deficit of $104.5 million.

Risks

The company's ability to continue as a going concern is uncertain due to its inability to sustain operations with current revenues.
The company is subject to risks common to smaller commercial companies, including dependence on key individuals and products, and competition from larger companies.
The company's revenues are not able to sustain its operations, and concerns exist regarding the company's ability to meet its obligations as they become due.
The company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies.

Future Outlook

The company plans to expand its brand name products, expand its product portfolio, evaluate acquisition targets, vertically integrate the supply chain, and access capital markets through equity offerings. Management is also considering postponing certain repayments of suppliers and creditors.

Management Comments

Management has expressed substantial doubt about the company's ability to continue as a going concern.
Management is considering postponing certain repayments of suppliers and creditors.
Management plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution.
Management will also consider postponing the repayment of its outstanding Trade Facility ($1,588,163 balance as of September 30, 2024), intends to make substantial efforts to receive additional debt financing through its subsidiary, Cosmofarm SA, and plans to raise additional equity funds through utilizing its outstanding warrants.

Industry Context

The company operates in the nutraceuticals, pharmaceuticals, and healthcare distribution sectors, which are subject to competition, regulatory changes, and economic conditions. The company is expanding its distribution network and product portfolio to compete in these markets.

Comparison to Industry Standards

The company's revenue growth of 7.1% for the nine-month period is below the average growth rate for the pharmaceutical and nutraceutical industries, which have seen double-digit growth in recent years.
The company's net loss of $6.6 million for the nine-month period is significantly higher than the average profitability of its peers, which are generally profitable or have lower losses.
The company's working capital of $11 million is below the industry average for companies of its size, indicating potential liquidity issues.
The company's accumulated deficit of $104.5 million is significantly higher than the industry average, indicating a history of losses and potential financial instability.
The company's reliance on debt financing and equity offerings to fund its operations is higher than the industry average, indicating a potential risk of financial distress.

Legal Proceedings

The company is involved in several ongoing legal proceedings, including a dispute with the National Medicines Agency regarding a wholesale license, a tax audit appeal, and various cases of dishonored checks.
Cana Laboratories has two pending lawsuits against Euaggelismos Hospital for a total sum of EUR 526,436 due to unpaid bills.
Cana Laboratories has an unasserted claim against Papanikolaou Hospital for a total sum of EUR 89,300 due to unpaid bills.
A lawsuit dated April 5, 2018 against the Companys subsidiary Cana Laboratories by a former employee before the Athens court of instance was initially heard on October 12, 2018.

Related Party Transactions

The company has significant related party transactions with Doc Pharma S.A., including purchases of inventory, pharmaceutical licenses, and sales.
The company has a loan receivable from Doc Pharma S.A.
The company has a prepaid balance with Doc Pharma related to purchases of inventory and pharmaceutical and nutraceutical licenses.
The company has transactions with Maria Kozari's pharmacy, including sales and outstanding receivables.
The company has a balance of $731,000 relating to unpaid salaries and bonuses due to Grigorios Siokas, the CEO of the Company and $188,000 due to George Terzis, the CFO of the Company.
The company has a net payable balance of $29,832 due to Konstantinos Gaston Kanaroglou, former manager and current employee of the Companys wholly owned subsidiary Cana.

Stakeholder Impact

Shareholders face significant risk due to the company's going concern uncertainty and potential for dilution from equity offerings.
Employees may be concerned about job security due to the company's financial instability.
Customers may be concerned about the company's ability to fulfill orders and provide ongoing services.
Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

The company plans to expand its brand name products to the market.
The company plans to expand its current product portfolio.
The company plans to evaluate acquisition targets to expand distribution.
The company intends to vertically integrate the supply chain distribution network.
The company plans to further access the capital markets in order to raise additional funds through equity offerings.
Management will also consider postponing the repayment of its outstanding Trade Facility.
The company intends to make substantial efforts to receive additional debt financing through its subsidiary, Cosmofarm SA.
The company plans to raise additional equity funds through utilizing its outstanding warrants.
The company plans to file with the U.S. SEC a registration statement on Form S-1 for an offering of up to $7.5 million by the end of November 2024.
The company's management is considering postponing certain repayments of suppliers and creditors.

Key Dates

Date	Description
2018-10-17	The Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was 4,866,910 ($5,629,555) and related accrued interest of 453,094 ($524,094) would be split into two principal balances of Euro 2,000,000 ($2,316,000), (the 'EURO Loan') and USD $4,000,000 (the 'USD Loan').
2020-05-12	The Companys subsidiary, SkyPharm, was granted and on May 22, 2020 received a 300,000 ($366,900) loan from the Greek government.
2020-06-23	The Companys subsidiary, Cosmofarm, entered into an agreement with the National Bank of Greece S.A. (the Bank) to borrow a maximum of 500,000 ($611,500).
2020-06-24	The Companys subsidiary, Decahedron, received a loan 50,000 ($68,310) from the United Kingdom government.
2020-11-19	The Company entered into an agreement with a third-party lender in the principal amount of 500,000 ($611,500).
2021-07-30	The Company entered into an agreement with a third-party lender in the principal amount of 500,000 ($578,850).
2022-06-09	The Company entered into an agreement with a third-party lender in the principal amount of 320,000 ($335,008).
2023-06-15	Cosmos Health Inc. entered into an Assignment and Assumption Agreement with Ioannis Bikas O.E., a Greek Company (Bikas).
2023-06-30	The Company acquired Cana Laboratories Holdings (Cyprus) Limited (Cana).
2023-07-14	The Company entered into an agreement with a third-party lender in the principal amount of 1,000,000 ($1,123,700).
2024-01-23	The Company completed the acquisition of Cloudscreen.
2024-07-29	The Companys subsidiary Cosmofarm SA entered into an agreement with a third-party lender in the principal amount of 400,000 ($432,760).
2024-09-26	The Company entered into a Warrant Inducement Letter with an investor.
2024-09-30	End of the reporting period for the third quarter results.
2024-11-06	The Company received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price.
2024-11-14	Date of the filing of the 10-Q report.

Keywords

pharmaceuticals, nutraceuticals, healthcare, distribution, financial results, going concern, warrants, debt financing, equity offering, Cosmos Health

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.